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Abstract
Background: Mirabegron is a β3-adrenoreceptor agonist developed for treatment of overactive bladder (OAB).
α1-Adrenergic receptor blockers are effective for lower urinary tract symptoms (LUTS) in male patients. However,
the efficacy of mirabegron additional treatment in elderly male patients with persistent male LUTS, especially in
OAB after monotherapy with α1-adrenergic blockers, is not fully understood.
Methods: This study was conducted in male LUTS patients who were ≥ 65 years of age and had persistent OAB
symptoms, regardless of whether they took an α1-adrenergic receptor blocker orally. Before and 12 weeks after
mirabegron additional therapy (50 mg once daily), we evaluated the efficacy of this treatment using the Overactive
Bladder Symptom Score (OABSS) and International Prostate Symptom Score (IPSS), and changes in the maximum
flow rate (Qmax) and post-void residual urine volume (PVR). We evaluated patients overall and divided into two
groups by age: young-old (from 65 to 74 years old) and old-old (from 75 to 84 years old).
Results: Fifty men were enrolled in this study. Mirabegron additional therapy improved the total OABSS, total IPSS,
and IPSS-quality of life (QOL) score. The voided volume (VV) and Qmax improved after treatment in patients overall.
However, there was no significant change in PVR. The total OABSS, total IPSS, and IPSS-QOL score significantly
improved in both of the young-old and old-old groups. However, a significant increasing of VV was detected in the
young-old group. There were no significant differences in the Qmax or PVR in either group.
Conclusions: Mirabegron additional therapy was effective for male patients whose persistent LUTS and particularly
OAB was not controlled with α1-adrenergic receptor blocker monotherapy, and mirabegron did not have negative
effects on voiding function. Additionally, mirabegron additional therapy was considered effective regardless of
patient age.
Trial registration: Trial registration number (TRN) trial registration number (TRN) and date of registration:
ISRCTN16759097 in July 8, 2016.
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Background
Overactive bladder (OAB) is defined as a condition with
characteristic symptoms of urinary urgency that is usu-
ally accompanied by frequency and nocturia, with or
without urgency incontinence [1]. It is particularly bur-
densome to older people because of its higher preva-
lence, and because the impact of its symptoms may be
more pronounced due to the increased burden of
chronic comorbidities [2, 3]. The symptoms caused by
OAB decrease patients’ quality of life (QOL), and OAB
can lead to various pathological conditions such as in-
creases in the fracture rate, sleep disturbances, and de-
pressive feelings) [4, 5]. Anti-muscarinic agents are often
used as first-line therapy for patients with OAB. How-
ever, unfortunately, about a third quarter of patients
cannot continue taking these drugs due to unsatisfactory
efficacy and various adverse events [6, 7].
In addition, mainly due to the adverse effects of anti-
muscarinic drugs, Japanese clinical guidelines for both
male lower urinary tract symptoms (LUTS) and benign
prostatic hyperplasia recommend physicians to use α1-
adrenergic blockers as the first choice drug for male
LUTS patients regardless of the presence or absence of
OAB symptoms [8, 9].
Mirabegron is a β3-adrenoceptor agonist approved for
treating OAB in Europe, the United States, Canada,
Japan, and Australia [10]. Mirabegron is a specific agon-
ist, acting on β3-adrenoceptors in the human detrusor,
the stimulation of which leads to active relaxation of the
human detrusor in the storage phase, which increases
bladder capacity without exerting an effect on voiding
[11]. The efficacy and safety of mirabegron have been
studied in several randomized trials. For example,
SCORPIO, a large, randomized, placebo-controlled
phase III study, evaluated the efficacy, safety, and toler-
ability of mirabegron over 12 weeks in patients with
OAB [12], and TAURUS, a 1-year, randomized, double-
blind, safety study, evaluated the safety, tolerability, and
efficacy of mirabegron [13]. Both studies mainly im-
proved storage symptoms, including urgency incontin-
ence and increased voiding volume, and demonstrated
that the efficacy of mirabegron lasted 4 weeks later and
continued until the end of the observation periods. Fur-
thermore, the rate of adverse events due to 50 mg mira-
begron was similar to that of a placebo, and significantly
lower than that of the anti-muscarinic drug tolterodine
(4 mg) [12, 13]. In addition, other researchers have re-
ported that mirabegron add-on therapy combined with
α1-adrenergic receptor blockers is very effective for stor-
age symptoms, even in male patients with OAB [14–16].
However, no studies have focused on elderly male pa-
tients aged 65 years old and over.
To our knowledge, the present study is the first to
focus on the efficacy of mirabegron additional therapy in
elderly male patients with OAB after treatment with α1-
adrenergic receptor blocker monotherapy.
Methods
This prospective study was conducted in male patients
who were 65 years or older in age, had persistent LUTS
and particularly OAB symptoms, and had been taking a
regular dose of α1-adrenergic receptor blockers for more
than 12 weeks. OAB was diagnosed using the Overactive
Bladder Symptom Score (OABSS), and persistent OAB
symptoms were defined as a total OABSS of 3 or more
points with urinary urgency at least once per week [17].
Exclusion criteria were a post-void urine volume (PVR)
of 50 mL, history of urinary retention, prior diagnosis of
neurogenic bladder, urethral stricture, severe hyperten-
sion (systolic blood pressure ≥ 180 mmHg and/or dia-
stolic blood pressure ≥ 110 mmHg) not well controlled
by medication, renal insufficiency (glomerular filtration
rate < 30 mL/min/1.73 m2), liver impairment, intention
to have a child, urological malignancy, patients taking
any anti-muscarinic drugs, or those considered unsuit-
able for the trial by the treating physicians.
The patients continued all of their prescribed drugs
during this study period. Before and 12 weeks after mir-
abegron (Betanis®, Astellas Pharma Inc., Tokyo, Japan;
50 mg once daily) treatment was added to a previous
α1-adrenergic receptor blocker for urinary symptoms,
we evaluated the efficacy of the treatment using the
OABSS and International Prostate Symptom Score
(IPSS) to assess subjective symptoms, and we used uro-
flowmetry and PVR to assess objective symptoms. We
measured the maximum flow rate (Qmax) using the
Duet® Logic G2 system (Mediwatch UK Ltd., Rugby, UK)
on free uroflowmetry and PVR using transabdominal
ultrasound sonography (HI VISION Avius®, Hitachi-
Aloka Medical, Ltd, Tokyo, Japan). Moreover, before
mirabegron add-on treatment was administered, we
evaluated the prostate volume (PV) using transabdom-
inal ultrasound sonography.
The primary endpoint was the change in total OABSS.
The secondary endpoints evaluated were the change in
the subscale scores of the OABSS, total IPSS, each sub-
scale score of the IPSS and IPSS-QOL, voided volume
(VV) on free uroflowmetry, Qmax, and PVR. In this
study, we compared these subjective and objective pa-
rameters between two groups defined according to the
patients’ age: young-old (from 65 to 74 years old) and
old-old (from 75 to 84 years old).
During the clinical study, the current α1-adrenergic
receptor blocker that the patients had been taking orally
was not changed to a different one. Additionally, no pa-
tients were taking multiple α1-adrenergic receptor
blockers. The safety assessment included a change in ad-
verse events. We observed patients’ complaints of
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adverse effects, and information on the adverse events
was recorded throughout the study period.
All statistical analyses were performed using computer
software (JMP 10; SAS Institute Inc., Cary, NC, USA).
Differences in the changes in patients’ parameters from
baseline to 12 weeks were examined using the Wilcoxon
signed-rank test. P < 0.05 was considered statistically
significant.
Results
Fifty men were enrolled in this study. As shown in
Table 1, overall, the mean ± standard deviation (SD) of
patients’ age was 75.7 ± 7.6 years, and the mean ± SD PV
was 33.7 ± 8.6 mL. All patients had taken a previous α1-
adrenergic receptor blocker, including silodosin (26 pa-
tients), naftopidil (15), tamsulosin (8), and urapidil (1).
Among the 50 patents, 22 (44.0 %) and 28 (56.0 %) were
classified into the young-old group and old-old group,
respectively. No other demographic or clinical parame-
ters significantly differed between the young-old and
old-old groups.
Figure 1a shows the change in the OABSS before and
after mirabegron add-on treatment was administered to
patients overall. Mirabegron add-on treatment improved
the total OABSS (from 6.0 ± 2.1 to 4.4 ± 1.4, P < 0.001),
and the nighttime frequency (OABSS Q2, P < 0.001) and
urgency (OABSS Q3, P < 0.001) subscale scores of the
OABSS after the 12-week treatment period. Although
the urgency incontinence subscale score (OABSS Q4)
improved after 12 weeks compared to that before treat-
ment, the difference did not reach statistical significance
(P < 0.05). Similarly, mirabegron add-on treatment sig-
nificantly improved the total IPSS (before 15.1 ± 4.2 to
11.8 ± 4.6, P < 0.001); frequency (IPSS Q2, P < 0.001), ur-
gency (IPSS Q4, P < 0.001), and nocturia subscales (IPSS
Q7, P < 0.001); and IPSS-QOL score (P < 0.001) after
treatment (Fig. 1b). There were no significant differences
in voiding symptoms, including incomplete emptying,
intermittency, weak stream, and straining before and
after 12-week mirabegron add-on treatment.
In the entire patient, changes in the objective pa-
rameters of VV, Qmax, and PVR are shown in Fig. 2.
VV on free uroflowmetry increased from 137.3 ±
62.9 mL to 154.1 ± 64.1 mL after treatment (P = 0.005).
Similarly, Qmax improved from 9.1 ± 3.7 mL/s to 11.1 ±
3.6 mL/s (P = 0.036). However, no significant change was
detected in PVR (from 23.1 ± 15.6 mL to 27.3 ± 21.5 mL,
P = 0.349).
Next, changes of these parameters on subjective symp-
toms and objective measurements depending on age
(young-old and old-old group) were showed in Table 2.
The total OABSS and nighttime frequency (OABSS Q2),
and urgency (OABSS Q3) subscales were improved in
both groups. However, urgency incontinence (OABSS Q4)
was improved only in the young-old group (P = 0.021; old-
old group, P = 0.686). Significant improvements were also
observed in the total IPSS; IPSS-QOL; and frequency
(IPSS Q2), urgency (IPSS Q4), and nocturia (IPSS Q7)
subscales in both groups. No IPSS-related parameter sig-
nificantly differed between the young-old group and the
old-old group. However, although all IPSS parameters
were unchanged or decreased in the young-old group after
treatment, incomplete emptying (Q1), intermittency (Q3),
weak stream (Q5), and straining (Q6) had a tendency to
increase after treatment in the old-old group.
Among the objective symptoms, VV on free uroflow-
metry increased after treatment in the young-old group
(P = 0.012) but not in the old-old group (P = 0.113).
There were no significant changes in the Qmax and
PVR after treatment in either group.
A safety analysis was performed on all patients dur-
ing the clinical trial. Two patients (4 %) complained
of dry mouth. One patient (2 %) complained of con-
stipation. However, since these adverse effects were
very mild, the patients did not need to stop taking
mirabegron. In addition, none of the patients with
hypertension experienced worsening of their blood
pressure levels. Hence, all patients completed this
clinical study, including all scheduled examinations
during the study period.
Table 1 Patients’ characteristics
Overall Young-old group Old-old group P valuea
Number of patients (N/%) 50 22 (44.0) 28 (56.0) -
Age (years) 75.7 ± 7.6 68.7 (2.7) 81.1 (5.3) < 0.001
Prostate volume (mL) 33.7 ± 8.6 33.5 (7.6) 33.7 (9.5) 0.961
α1-adrenergic receptor blocker
Silodosin (N/%) 26 (52.0) 13 (59.1) 13 (46.4)
Naftopidil 15 (30.0) 5 (22.7) 10 (35.7)
Tamsulosin 8 (16.0) 3 (13.6) 5 (17.9)
Urapidil 1 (2.0) 1 (4.5) 0 (0)
Data are shown as mean ± standard deviation
aDifference between the young-old group and old-old group
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Discussion
To the best of our knowledge, the present study is the
first to focus on the efficacy of mirabegron additional
therapy in elderly male patients with OAB after mono-
therapy with α1-adrenergic receptor blockers. Our find-













Mean 1.2 1.4 2.1 1.5 2.4 1.2 0.5 0.3 6.0 4.4
SD 0.8 0.6 0.9 0.7 0.8 0.8 1.0 0.5 2.1 1.4





























P = .215 P < .001 P = .551 P < .001
0     12 0     12 0    12
Q3: Intermittency






























Mean 2.2 2.1 1.6 1.5 3.1 2.1 15.1 11.8
SD 1.0 1.1 1.2 1.1 0.8 1.4 4.2 4.6
0     12 0     12 0     12 0     12Week (s)














Mean 8.9 5.7 6.2 6.1 4.2 3.4
SD 1.8 2.2 3.4 .6 0.9 1.2
P < .001 P < .001P = .562
Storage symptoms
(Q2+Q4+Q7)
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a
b
Fig. 1 Changes in subjective symptoms. a shows changes in the Overactive Bladder Symptom Score (OABSS). Combination therapy with α-1
adrenergic receptor blocker and mirabegron for 12 weeks significantly improved the total OABSS, nighttime frequency (Q2), and urgency (Q3).
b shows the change in the International Prostate Symptom Score (IPSS). Combination therapy significantly improved the IPSS total score, IPSS-quality
of life, and storage symptoms (frequency [Q2], urgency [Q4], nocturia [Q7], and IPSS-storage symptoms [Q2 + Q4 + Q7]). However, combination therapy
did not affect voiding symptoms (incomplete emptying [Q1], intermittency [Q3], weak stream [Q5], straining [Q6], and IPSS-voiding symptoms [Q1 +
Q3 +Q5 + Q6]). The white columns show the scores at 0 weeks, and the black columns show scores at 12 weeks. SD, standard deviation





















Mean 137.3 154.1 9.1 11.1 23.1 27.3
SD 62.9 64.1 3.7 3.6 15.6 21.5
Week (s) 0     12 0      12 0      12
Voided volume Maximum flow rate Post-void 
residual urine
P = .005 P = .036 P = .349
Fig. 2 Changes in the measurements of objective symptoms in patients overall. The white columns show the values at 0 weeks, and the black
columns show those at 12 weeks. After 12 weeks of α1-adrenergic receptor blocker and mirabegron combination therapy, the voided volume
and maximum flow rate improved significantly. Post-void residual urine increased at the end of the period; however, this change was not statistically
significant. SD, standard deviation
Table 2 Changes in the values of the subjective and objective symptoms in each group of elderly male patients with overactive
bladder
Young-old group (N = 22) Old-old group (N = 28)
0 W 12 W P Value 0 W 12 W P Value
OABSS
Q1 Daytime frequency 1.1 ± 0.7 1.4 ± 0.8 0.307 1.1 ± 0.8 1.4 ± 0.5 0.148
Q2 Nighttime frequency 2.1 ± 1.0 1.5 ± 0.9 0.034 2.0 ± 0.8 1.5 ± 0.6 0.005
Q3 Urgency 2.7 ± 1.1 1.2 ± 1.1 < 0.001 2.2 ± 0.4 1.3 ± 0.6 < 0.001
Q4 Urgency incontinence 0.9 ± 1.3 0.3 ± 0.6 0.021 0.2 ± 0.4 0.3 ± 0.4 0.686
Total score 6.5 ± 2.7 4.4 ± 1.6 0.004 5.6 ± 1.3 4.2 ± 1.2 < 0.001
IPSS
Q1 Incomplete emptying 1.2 ± 1.4 1.2 ± 1.3 1.000 1.2 ± 1.0 1.4 ± 1.2 0.093
Q2 Frequency 3.0 ± 1.1 2.0 ± 1.0 0.001 3.1 ± 0.7 2.1 ± 0.9 < 0.001
Q3 Intermittency 1.4 ± 1.3 1.2 ± 1.3 0.205 1.0 ± 1.0 1.1 ± 1.2 0.529
Q4 Urgency 2.8 ± 0.8 1.7 ± 0.9 < 0.001 2.6 ± 0.8 1.5 ± 1.0 < 0.001
Q5 Weak stream 2.2 ± 1.1 2.0 ± 1.2 0.142 2.2 ± 1.0 2.3 ± 1.0 0.689
Q6 Straining 2.0 ± 1.5 1.7 ± 1.4 0.110 1.3 ± 0.8 1.4 ± 0.9 0.529
Q7 Nocturia 3.3 ± 0.8 2.3 ± 1.4 0.001 2.9 ± 0.8 1.9 ± 0.9 < 0.001
Total score 16.0 ± 5.1 12.0 ± 5.3 < 0.001 14.5 ± 3.3 11.7 ± 4.1 < 0.001
Storage symptoms (Q2 + Q4 + Q7) 9.1 ± 1.9 6.0 ± 2.5 < 0.001 8.7 ± 5.6 5.6 ± 2.0 < 0.001
Voiding symptoms (Q1 + Q3 + Q5 + Q6) 6.8 ± 4.4 6.0 ± 4.4 0.029 5.8 ± 2.5 6.1 ± 3.0 0.102
QOL score 4.3 ± 1.0 3.5 ± 1.4 0.006 4.1 ± 0.8 3.2 ± 1.0 < 0.001
Urodynamic study
VV (mL) 141.0 ± 78.1 169.5 ± 74.0 0.012 134.4 ± 49.2 142.0 ± 53.4 0.133
Qmax (mL/s) 9.1 ± 3.0 9.9 ± 2.7 0.159 9.1 ± 2.2 12.0 ± 12.4 0.116
PVR (mL) 27.4 ± 41.8 22.1 ± 22.7 0.879 26.5 ± 17.3 30.4 ± 25.9 0.190
OABSS overactive bladder symptom score, IPSS international prostate symptom score, w week, VV voided volume, Qmax maximum flow rate, PVR post-void
residual urine
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effective for those whose OAB was not controlled with
α1-adrenergic receptor blockers, according to the
OABSS and IPSS. Our results also demonstrated that
mirabegron had no suppressive effects on voiding func-
tion on uroflowmetry and PVR. In addition, regardless
of the patient’s age, mirabegron add-on therapy was con-
sidered effective and safe to take orally.
In elderly patients with benign prostatic hyperplasia,
an α1-adrenergic receptor blocker significantly improved
LUTS, especially voiding dysfunction. However, some
patients may continue to suffer from storage symptoms
such as urgency and frequency. For these patients, some
studies have suggested that combination therapy with an
α1-adrenergic receptor blocker and anti-muscarinic drug
is effective [18, 19]. However, because of the impaired
physiological function of elderly people, anti-muscarinic
drugs carry the risk for adverse events. In fact, there is a
significant incidence of peripheral anti-muscarinic ad-
verse events such as dry mouth, constipation, tachycar-
dia, cognitive dysfunction, and voiding dysfunction in
elderly patients [20, 21]. Voiding dysfunction, in particu-
lar, due to male LUTS, might lead to excessive residual
urine, urinary tract infection, and post-renal renal
failure.
Mirabegron, a β3-adrenergic receptor agonist, is a new
type of agent for OAB, with a reported adverse effect
rate almost as low as that of a placebo [15, 22]. However,
recently, concerns have been raised regarding the use of
mirabegron to treat OAB patients with severe hyperten-
sion (systolic blood pressure ≥ 180 mmHg and/or dia-
stolic blood pressure ≥ 110 mmHg) [23]. In addition, no
studies have targeted elderly male patients 65 years old
and over, who are more prone to experiencing complica-
tions than younger patients.
According to the present study, mirabegron additional
therapy improved storage symptoms on the OABSS and
IPSS regardless of age. In addition, mirabegron add-
itional therapy improved storage symptoms and voiding
symptoms on the IPSS in the young-old patient group.
Previous studies have reported that mirabegron im-
proved the OABSS and the total and storage symptoms
on the IPSS in male patients with OAB [15, 16, 24].
Moreover, Wada et al. suggested that mirabegron add-
on treatment with tamsulosin improved storage
symptoms and voiding symptoms [16]. However, these
previous studies were complex, as they included patients
of various ages and they had small sample sizes; no
study has focused only on older male patients. Ichihara
et al. reported that combination therapy with tamsulosin
and mirabegron was effective for persistent OAB symp-
toms with benign prostatic obstruction after tamsulosin
monotherapy [15]. They divided the patients into two
groups, tamsulosin monotherapy (N = 38) and combin-
ation therapy with tamsulosin and mirabegron (N = 38).
Although average age of their study cohort was very
similar to that of the present study (74.5 ± 8.2 vs. 75.7 ±
7.6 years), they included male patients aged 50 years or
older. Hence they did not target only elderly male LUTS
patients. In addition, the number of patients receiving
combination therapy with tamsulosin and mirabegron
was lower in the previous study compared to ours.
Upon further stratifying our study subjects according
to age, our results suggested that voiding symptoms
worsened slightly after treatment in the old-old patient
group, but this difference was not statistically significant.
These findings indicate that the use of mirabegron in
elderly patients should be carefully monitored, especially
in older patients .
The objective symptoms VV and Qmax on uroflowme-
try were improved after treatment in patients overall.
VV was particularly improved after treatment in young-
old patients. However, objective symptoms did not
change significantly in the old-old patient group. A pre-
vious pressure-flow study reported that mirabegron did
not affect urinary bladder contraction even if older male
patients were included in the analysis [16, 25]. However,
these studies indicated that mirabegron therapy possibil-
ity increased PVR, although the change was not statisti-
cally significant. In our study, we obtained similar results
for PVR. The older patients’ voiding functions declined
physiologically, and their initial PVR volume was higher
than that of the younger patients [26]. Although many
clinicians think that mirabegron is associated with fewer
problems in terms of voiding function than anti-
cholinergic agents, it is necessary to consider changes in
both the subjective and objective symptoms after treat-
ment with mirabegron, especially in old-old patients.
In the present study, only three patients (6 %) had
mild adverse effects (2 patients, thirst; 1 patient, consti-
pation), and all patients continued to take mirabegron
during the study period. None of the patients with
hypertension experienced worsening of their blood pres-
sure level, although hypertension was well-controlled by
medication or not severe in all cases in the present
study. Hence, it appears that mirabegron can be used
safely, and it has good tolerability. Previous studies have
reported that typical adverse events such as dry mouth
and constipation occurred at a similar incidence between
mirabegron and placebo treatment [10, 12, 27]. The inci-
dence of dry mouth with mirabegron, in particular, is
three- to four-fold lower than that with tolterodine. As
noted in a meta-analysis, anti-muscarinic drugs are asso-
ciated with a 29.6 % incidence of dry mouth [27]. As dry
mouth is reported to be an important factor determining
persistence, the favorable tolerability profile of mirabe-
gron may result in improved treatment adherence com-
pared with anti-muscarinic drugs, which has important
implications for patient outcome [10]. Many elderly
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people suffer from constipation and dry mouth; thus
mirabegron may be convenient to administer in the eld-
erly with OAB [28, 29].
The present study has several limitations, the major
one being that the number of patients included was very
small. The observation period was also limited to only
12 weeks. In addition, this study was open label, not pla-
cebo controlled. Moreover, patients with relatively mild
voiding symptoms prior to mirabegron treatment (with
IPSS subscale scores for voiding symptoms of 6.8 ± 1.4,
and PVR of 27.4 ± 41.8 mL) and with low prostate vol-
ume (33.7 ± 8.6 mL) unlikely to conducting the urinary
dysfunction were mainly included in this study. These
factors may have contributed to the low complication
rate observed in this study. However, despite these limi-
tations, this is the first prospective study that specifically
evaluated elderly male patients with OAB who were ad-
ministered mirabegron additional therapy after treat-
ment with α1-adrenergic receptor blockers. In recent
years, there has been growing interest in the efficacy and
safety of mirabegron for elderly patients [30]. We believe
that in spite of its small sample size, this investigation
contributes important information to the selection of
treatment strategies in elderly patients with lower urin-
ary tract symptoms.
Conclusions
Our results indicate that mirabegron additional treat-
ment is effective, safe, and tolerable therapy for persist-
ent OAB in elderly male patients after monotherapy
with α1-adrenergic receptor blockers. In addition, mira-
begron additional therapy was considered effective re-
gardless of the patient’s age.
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